Skip to main content

Table 6 Prevalence ratio of PCC for TTI of 7–10 days versus 1–6 days (N = 409)

From: COVID-19 monoclonal antibody treatment impact on symptoms and post-COVID conditions among high-risk patients at a Federally Qualified Health Center

Model

PR

95% CI

P-value

Crude (unadjusted)

1.02

0.90 to 1.16

0.75

Model 1: crude + demographic characteristics*

1.02

0.89 to 1.16

0.79

Model 2: model 1 + clinical characteristics**

1.01

0.89 to 1.16

0.84

  1. Modified Poisson regressions with robust standard errors performed. Results are for time to infusion of 7–10 days (n = 206) compared to the reference group, time to infusion of 1–6 days (n = 203). PCC was defined by PCC Definition 1 (≥ 1 symptom at D28 + Survey). Original N = 411; analysis excludes 2 patients with outlier times to infusion
  2. CI confidence interval, PCC post-COVID conditions, PR prevalence ratio, TTI time to mAb infusion
  3. *Model 1 was adjusted for demographic characteristics (age, sex assigned at birth, race, and ethnicity) only
  4. **Model 2 was adjusted for demographic characteristics (age, sex assigned at birth, race, and ethnicity) plus clinical characteristics (vaccination status pre-infusion, mAb infusion type, and number of symptoms at Baseline Survey)